Fortaleza Asset Management Inc. Decreases Position in Supernus Pharmaceuticals, Inc. (SUPN)

Fortaleza Asset Management Inc. trimmed its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 47.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,710 shares of the specialty pharmaceutical company’s stock after selling 2,415 shares during the period. Fortaleza Asset Management Inc.’s holdings in Supernus Pharmaceuticals were worth $108,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Meeder Asset Management Inc. raised its holdings in shares of Supernus Pharmaceuticals by 3,455.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Supernus Pharmaceuticals by 278.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,462 shares in the last quarter. Advisor Group Inc. raised its holdings in shares of Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after buying an additional 410 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Supernus Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 517 shares in the last quarter. 95.06% of the stock is currently owned by institutional investors.

In other news, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total value of $4,426,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $47.60, for a total value of $2,380,000.00. The disclosure for this sale can be found here. Insiders sold a total of 153,709 shares of company stock valued at $7,223,108 over the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) traded down 0.12% during trading on Wednesday, reaching $41.55. The company’s stock had a trading volume of 21,948 shares. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of 20.96 and a beta of 1.30. Supernus Pharmaceuticals, Inc. has a 12-month low of $17.25 and a 12-month high of $50.04. The company has a 50 day moving average of $41.72 and a 200-day moving average of $40.29.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. Analysts forecast that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current year.

A number of brokerages recently weighed in on SUPN. Cantor Fitzgerald raised their price objective on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a report on Wednesday, July 5th. Stifel Nicolaus cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price objective on the stock. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $45.00 price target on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Cowen and Company reaffirmed a “positive” rating and issued a $50.00 price target (up from $40.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 3rd. Finally, BidaskClub cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $48.38.

TRADEMARK VIOLATION WARNING: This article was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/11/01/fortaleza-asset-management-inc-decreases-position-in-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit